These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1882 related items for PubMed ID: 15793561

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project.
    Lancet; 2006 Jun; 365(9464):1054-61. PubMed ID: 15781101
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of tyrosine kinases and phosphatases in polycythemia vera.
    Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN.
    Semin Hematol; 2005 Oct; 42(4):221-9. PubMed ID: 16210035
    [Abstract] [Full Text] [Related]

  • 13. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W, Constantinescu SN.
    Hematology Am Soc Hematol Educ Program; 2005 Dec; ():195-200. PubMed ID: 16304380
    [Abstract] [Full Text] [Related]

  • 17. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ, McMullin MF.
    Hematol Oncol; 2005 Dec; 23(3-4):91-3. PubMed ID: 16285006
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.
    N Engl J Med; 2007 Feb 01; 356(5):459-68. PubMed ID: 17267906
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 95.